Home / Resources / Regulatory resources

薬事規制

最新のリソース

Certara Announces Expansion of Clinical Technology Collaboration with Merck

サターラ、メルク社との臨床技術提携の拡大を発表

プレスリリース

MIDD can ease pediatric & rare disease drug loss in Japan

日本における小児・希少疾患領域のドラッグ・ロス解消に向けて

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

注目コンテンツ

The Do’s and Don’ts of Define.xml

The Do’s and Don’ts of Define.xml

Upcoming regulatory webinars

ウェビナー

Transform Your PK/PD Workflow with AI and the Cloud

2025年7月10日 – 11am ET

ウェビナー

Faster Mapping from Source Data to Target SDTM

July 15 – 10am ET & July 17 – 11am IST

ウェビナー

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

2025年7月17日 – 11am ET

Latest regulatory blogs

日本における小児・希少疾患領域のドラッグ・ロス解消に向けて

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

The Do’s and Don’ts of Define.xml

FDA ESG NextGen for Regulatory Submissions

CERTAINTY 2025: The power of Model-Informed Drug Development

SEND V4.0 – What to Expect and When to Expect It

以下のイベントで弊社のエキスパートをご紹介

展示会・学会

ISSX 2025 International Meeting

September 12 - 14, 2025 – Chicago, Illinois

展示会・学会

SCDM 2025 Annual Conference

September 27 - 30, 2025

展示会・学会

ACoP 2025

October 18 - 21, 2025

All regulatory resources

日本における小児・希少疾患領域のドラッグ・ロス解消に向けて

Certara Services, Clinical Pharmacology, Model Informed Drug Development, Modeling and Simulation, Pediatrics, Blog

Pirana Tips and Tricks – Report Object Generation in Pirana

サターラの製品、ウェビナー

SCDM 2025 Annual Conference

Certara Products - Pinnacle 21, Conference

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

Certara Products, Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Blog

The Do’s and Don’ts of Define.xml

CDISC, Certara Products - Pinnacle 21, Define-XML, Blog

How Model-informed drug development rescue projects from a risky situation

Certara Services, Clinical Pharmacology, Homepage Latest, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Case Study

Increasing Productivity In Pharma R&D Starts With Data

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Homepage Latest, Press Coverage

FDA ESG NextGen for Regulatory Submissions

Certara Products - GlobalSubmit, Blog

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Certara Services, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Therapeutic Specialties, Publication

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Infectious Disease, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Webinar

Faster Mapping from Source Data to Target SDTM

Certara Products - Pinnacle 21, Webinar

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Certara Products - Phoenix, Certara Products - Pinnacle 21, Certara Services, Clinical Pharmacology, Clinical Trials, Data Standards, Drug Development, Model Informed Drug Development, Modeling and Simulation - PK/PD, Webinar - Resources LP - Upcoming, Webinar

1
2
3
…
28
›

ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。

© 2025 Certara. All Rights Reserved. | 個人情報保護

Powered by Translations.com GlobalLink Web Software